Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Olaparib with Ceralasertib for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Trial Status: active

This phase II trial studies how well olaparib with ceralasertib works in treating patients with germline BRCA mutated breast cancer that has spread to other places in the body (advanced or metastatic). Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Olaparib is also used to help maintain the response of a certain type of pancreatic cancer that has not spread or progressed after the first chemotherapy treatment. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells. Giving olaparib with ceralasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.